Company Filing History:
Years Active: 2015-2020
Title: Innovations by Zheng Meng in Cancer Treatment
Introduction
Zheng Meng is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target cancer pathways. With a total of 2 patents, his work focuses on innovative solutions for treating clinical conditions related to cancer.
Latest Patents
Zheng Meng's latest patents include two groundbreaking inventions. The first patent is for N-(3-heteroarylaryl)-4-arylarylcarboxamides and analogs as hedgehog pathway inhibitors. This invention discloses novel compounds that can inhibit the hedgehog pathway, which is crucial in various cancer types. The second patent involves 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs, which serve as PARP inhibitors. These compounds are designed to treat clinical conditions responsive to the inhibition of PARP activity, further contributing to cancer treatment.
Career Highlights
Zheng Meng is currently associated with Impact Therapeutics, Inc., where he continues to innovate in the field of cancer therapeutics. His work is characterized by a strong focus on developing effective inhibitors that can potentially improve patient outcomes.
Collaborations
Zheng has collaborated with notable colleagues such as Suixiong Cai and Ye Edward Tian. These partnerships enhance the research and development efforts at Impact Therapeutics, Inc., fostering a collaborative environment for innovation.
Conclusion
Zheng Meng's contributions to cancer treatment through his innovative patents highlight the importance of research in developing effective therapies. His work continues to pave the way for advancements in medicinal chemistry and cancer therapeutics.